Last reviewed · How we verify
NCT05143827
Glycemic Index of Pasta From Traditional and Current Wheat Varieties
NA trial testing Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan) in Diabetes Type 2 in 30 participants. Status unknown.
31 August 2022
Quick facts
| Lead sponsor | Azienda Ospedaliero-Universitaria Careggi |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 20 November 2021 |
| Primary completion | 31 August 2022 |
| Estimated completion | 30 September 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)
- Pasta manufactured with current wheat varieties (Claudio)
Conditions studied
- Diabetes Type 2 — all drugs for Diabetes Type 2 →
Sponsor
Azienda Ospedaliero-Universitaria Careggi — full company profile →
Who can join
Adults 18 to 70, any sex, with Diabetes Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, cross-over study compares pasta produced with three different wheat varieties (Senatore Cappelli, Korasan, Claudio). Patients with type 2 diabetes with no pharmacological treatment will be randomized to three different sequences, and asked to eat a standard portion of pasta on three different occasions, four days apart. 3-hour post-prandial interstitial glucose profiles will be recorded using trans-cutaneous sensors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05143827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Type 2
Currently open trials in the same condition.
- NCT07176793 — Pregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes · recruiting
- NCT07485075 — Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical · NA · recruiting
- NCT07220213 — FELLAShip to Better Health · NA · recruiting
- NCT07350967 — Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel End · NA · recruiting
- NCT07149610 — Connected Care for Type 2 Diabetes Self-Management · NA · recruiting
Other Azienda Ospedaliero-Universitaria Careggi trials
Trials by the same sponsor.
- NCT07296055 — Endobronchial Valve in Tubercular and NTM Pulmonary Cavities. · NA · not yet recruiting
- NCT07289581 — Effect of Treatment With Butyric Acid in Anorexia Nervosa · NA · active not recruiting
- NCT06978608 — Ultrasound and Somatosensory Median Nerve Evaluation in CRPS I · not yet recruiting
- NCT07005882 — Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Ra · Phase 2 · not yet recruiting
- NCT06529601 — Comparison Between CAD/CAM and Conventional Mandibular Fixed Retainers. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05143827 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero-Universitaria Careggi
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05143827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing